Reference
Goldstein DA, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. 51st Annual Meeting of the American Society of Clinical Oncology : abstr. 6613, 29 May 2015. Available from: URL: http://abstracts.asco.org/156/AbstView_156_150950.html
Rights and permissions
About this article
Cite this article
Regorafenib not cost effective in mCRC. PharmacoEcon Outcomes News 732, 27 (2015). https://doi.org/10.1007/s40274-015-2293-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2293-5